Comment on: Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae

J Antimicrob Chemother. 2022 Sep 30;77(10):2892-2894. doi: 10.1093/jac/dkac150.

Authors

Marion Giry¹, Sacha Sarfati², Martine Pestel-Caron^{1

3}, Julien Wils², Fabien Lamoureux², Kévin Alexandre^{1

4}

Affiliations

¹ Normandie Univ, UNIROUEN, INSERM U1311 DYNAMICURE, F-76000 Rouen, France.
² CHU Rouen, Department of Pharmacology - Toxicology and Pharmacogenetics, F-76000 Rouen, France.
³ Normandie Univ, UNIROUEN, UNICAEN, INSERM U1311 DYNAMICURE, CHU Rouen, Department of Microbiology, F-76000 Rouen, France.
⁴ Normandie Univ, UNIROUEN, UNICAEN, INSERM U1311 DYNAMICURE, CHU Rouen, Department of infectious diseases, F-76000 Rouen, France.

PMID: 35538913
DOI: 10.1093/jac/dkac150

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Infusions, Intravenous
Klebsiella pneumoniae*
Microbial Sensitivity Tests
Penicillanic Acid / pharmacology
Penicillanic Acid / therapeutic use
Piperacillin* / pharmacology
Piperacillin* / therapeutic use
Piperacillin, Tazobactam Drug Combination

Substances

Anti-Bacterial Agents
Piperacillin, Tazobactam Drug Combination
Penicillanic Acid
Piperacillin